Presentation is loading. Please wait.

Presentation is loading. Please wait.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Published byAvis Byrd Modified over 6 years ago

Similar presentations

Presentation on theme: "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant."— Presentation transcript:

1 Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant Thaçi, MD, Andrew Blauvelt, MD, MBA, Kristian Reich, MD, Tsen-Fang Tsai, MD, Francisco Vanaclocha, MD, Külli Kingo, MD, PhD, Michael Ziv, MD, BSc, Andreas Pinter, MD, Sophie Hugot, MSc, Ruquan You, MSc, Marina Milutinovic, MD  Journal of the American Academy of Dermatology  Volume 73, Issue 3, Pages (September 2015) DOI: /j.jaad Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Study design. aTo maintain blinding, placebo injections matching the secukinumab regimen were given to subjects in the ustekinumab group. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Subject disposition. ∗Four subjects did not receive study treatment (2 withdrew consent; 1 because of technical problem; and 1 because of physician decision) and discontinued the study at randomization; 1 subject was excluded from all analyses because the informed consent form was obtained the day after study-related procedure. †In all, 25 subjects discontinued study treatment because of adverse event (7); lost to follow-up (3); protocol deviation (5); subject/guardian decision (7); physician decision (1); noncompliance with study treatment (1); and technical problem (1). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Efficacy over time to week 16. Improvement from baseline Psoriasis Area and Severity Index (PASI) score of 90% or more (PASI 90) (A), 100% (PASI 100) (B), or 75% or more (PASI 75) (C). D, Investigator global assessment 2011 modified version (IGA mod 2011) 0/1 response. E, Dermatology Life Quality Index (DLQI) 0/1 response. ∗P ≤ .0001, †P < .001, ‡P < .05. Missing values for PASI score response variables and IGA mod /1 response were imputed as nonresponses (nonresponder imputation). Only subjects who could be evaluated for a response were included (subjects who had missed all postbaseline values were excluded for that response variable). Missing values for DLQI were handled using last observation carried forward. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?
Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Assessing adherence with phototherapy protocols

Assessing adherence with phototherapy protocols

Similar presentations

Ads by Google